Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formulation and Food/pH Effect Study of Crelosidenib (LY3410738)
NCT06181084Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of crelosidenib in cholangiocarcinoma (CCA), glioma, chondrosarcoma and 2 more (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-Time Curve from Hour 0 to the Last Measurable Concentration at 48 hours, Area Under the Concentration from Hour 0 Extrapolated to Infinity at 48 hours and 1 more. Started Oct 2021; status: completed.
02
Drugs
crelosidenib
03
Conditions
cholangiocarcinoma (CCA)gliomachondrosarcomaacute myeloid leukemia (AML)solid tumor
Beyond the preview
Go deeper on NCT06181084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181084.